American Journal of Advanced Multidisciplinary Research and Innovation (AJAMRI)

E-ISSN: XXXX-XXXX ● Website: www.ajamri.com ● Email: editor@ajamri.com

Personalized mRNA Therapeutics: Integrating Artificial Intelligence, Genomics and Precision Healthcare

Solène Delecourt

Assistant Professor University of California, Berkeley

Abstract

Personalized mRNA therapeutics represent an emerging frontier in precision medicine, combining messenger RNA technology with genomics, artificial intelligence, and individualized clinical decision-making. Unlike conventional pharmaceutical approaches, mRNA platforms can be rapidly designed to encode therapeutic proteins, antigens, or other biologically relevant molecules, creating opportunities for patient-specific interventions. Advances in genomic sequencing, computational biology, machine learning, and lipid nanoparticle delivery are increasingly enabling the identification of molecular targets and the development of individualized mRNA constructs. This paper examines the technological foundations of personalized mRNA therapeutics and evaluates their potential applications in cancer immunotherapy, rare diseases, infectious diseases, protein replacement, and regenerative medicine. A qualitative and conceptual methodology is adopted to analyse the integration of genomics, artificial intelligence, mRNA design, delivery systems, and clinical decision-making. The analysis indicates that AI can support target identification, sequence optimisation, neoantigen prediction, patient stratification, and treatment-response modelling, while genomic information provides the molecular basis for individualised therapeutic design. Major challenges include delivery efficiency, RNA stability, immunogenicity, manufacturing scalability, computational bias, genomic privacy, regulatory complexity, and equitable access. The study proposes an integrated precision-mRNA framework connecting genomic profiling, AI-assisted target selection, computational sequence design, personalised manufacturing, and clinical monitoring. The paper concludes that personalized mRNA therapeutics could significantly expand the scope of precision healthcare, provided that technological innovation is accompanied by rigorous clinical validation, secure genomic-data governance, scalable manufacturing, and responsible regulatory frameworks.

Keywords: Personalized mRNA Therapeutics, Artificial Intelligence, Genomics, Precision Medicine, mRNA Technology, Cancer Immunotherapy, Lipid Nanoparticles, Machine Learning, Precision Healthcare, Personalized Medicine.

American Journal of Advanced Multidisciplinary Research and Innovation (AJAMRI)

E-ISSN: XXXX-XXXX ● Website: www.ajamri.com ● Email: editor@ajamri.com

1. Introduction

Healthcare is increasingly moving from a population-based treatment model towards a more individualised approach in which diagnosis and therapy are informed by a patient's molecular characteristics.

Traditional medicines are generally developed for groups of patients who share broad clinical characteristics. However, individuals with the same diagnosis can differ substantially in genetic profile, disease progression, immune response, and treatment sensitivity.

Precision medicine seeks to address this heterogeneity by integrating clinical, genomic, molecular, and environmental information into personalised healthcare decisions.

Recent advances in messenger RNA (mRNA) technology have created an important opportunity within this transition.

mRNA provides temporary instructions for cells to produce specific proteins. Rather than administering a protein directly, an mRNA therapeutic can provide the biological instructions required for the patient's cells to produce the desired molecule.

The success of mRNA vaccine platforms has demonstrated the potential of this technology at large scale. The next stage involves extending mRNA approaches towards increasingly personalised applications.

When combined with genomic sequencing and artificial intelligence, mRNA platforms could potentially support therapies designed around the molecular characteristics of individual patients.

2. Concept of Personalized mRNA Therapeutics

Personalized mRNA therapeutics can be conceptualised as a multi-stage process:

Patient Genomics → Molecular Target Identification → AI Analysis → mRNA Design → Delivery → Clinical Monitoring

The therapeutic molecule may be designed to address a particular molecular abnormality, stimulate an immune response, or replace a missing biological function.

Potential applications include:

- Personalised cancer vaccines.
- Protein replacement.
- Rare genetic diseases.
- Immunotherapy.
- Infectious disease.
- Regenerative medicine.

3. Research Objectives

This paper aims to:

1. Examine the scientific foundations of mRNA therapeutics.
2. Analyse the role of genomics in personalised mRNA development.

American Journal of Advanced Multidisciplinary Research and Innovation (AJAMRI)

E-ISSN: XXXX-XXXX ● Website: www.ajamri.com ● Email: editor@ajamri.com

3. Evaluate applications of artificial intelligence.
4. Examine personalised cancer vaccines and other therapeutic applications.
5. Assess delivery and manufacturing challenges.
6. Discuss ethical, regulatory, and privacy concerns.
7. Develop a conceptual framework for precision mRNA healthcare.
8. Identify future research directions.

4. Research Methodology

A qualitative, conceptual, and multidisciplinary methodology is used.

The study synthesises research across:

- Molecular biology.
- Genomics.
- RNA biotechnology.
- Artificial intelligence.
- Drug delivery.
- Precision medicine.
- Clinical oncology.
- Bioinformatics.

The proposed framework evaluates personalised mRNA therapeutics across five major stages:

Stage	Core Function
Genomic profiling	Identify patient-specific molecular characteristics
AI analysis	Predict relevant targets
mRNA design	Develop candidate therapeutic sequences
Delivery	Transport mRNA to appropriate cells
Clinical monitoring	Evaluate response and refine treatment

5. Biological Foundations of mRNA

Messenger RNA is a temporary molecular intermediary between DNA and protein production.

The simplified biological pathway is:

DNA → mRNA → Protein

An mRNA therapeutic therefore does not necessarily need to alter the patient's DNA.

Instead, the administered mRNA provides temporary instructions that cellular machinery can use to produce a desired protein.

This transient nature is one of the characteristics that makes mRNA an attractive therapeutic platform.

6. Structure of Therapeutic mRNA

A therapeutic mRNA molecule typically contains several functional elements.

These include:

- 5′ cap.
- 5′ untranslated region.
- Coding sequence.
- 3′ untranslated region.
- Poly(A) tail.

The design of these elements can influence:

- Translation efficiency.
- RNA stability.
- Cellular behaviour.
- Duration of protein production.

Computational optimisation can help researchers evaluate different sequence configurations.

7. Role of Genomics

Genomic sequencing provides information about genetic variation between individuals.

In precision medicine, genomic information can be used to identify:

- Disease-associated mutations.
- Tumour-specific mutations.
- Genetic deficiencies.
- Potential therapeutic targets.

For personalised cancer treatment, tumour sequencing can reveal mutations that distinguish cancer cells from normal cells.

Some of these mutations may generate neoantigens that can potentially be targeted by an immune response.

8. Artificial Intelligence in Personalized mRNA Therapeutics

AI can contribute throughout the therapeutic-development pipeline.

Potential applications include:

Target Identification

Machine-learning systems can analyse genomic and molecular datasets to identify potentially important therapeutic targets.

American Journal of Advanced Multidisciplinary Research and Innovation (AJAMRI)

E-ISSN: XXXX-XXXX ● Website: www.ajamri.com ● Email: editor@ajamri.com

Neoantigen Prediction
AI models can estimate which tumour-derived mutations are most likely to generate clinically relevant immune responses.

Sequence Optimisation
Algorithms can evaluate candidate mRNA sequences for characteristics associated with stability and translation.

Patient Stratification
Machine-learning models can help identify patient subgroups likely to respond differently to particular interventions.

Treatment Monitoring
AI can analyse clinical and molecular data to identify response patterns and potential treatment resistance.

9. AI-Assisted Neoantigen Prediction

Personalised cancer vaccines are among the most promising applications of the technology.
A simplified pathway is:

Tumour Sequencing
↓
Mutation Identification
↓
Neoantigen Prediction
↓
Candidate Ranking
↓
mRNA Vaccine Design
↓
Immune Activation

AI can analyse large numbers of tumour mutations and rank candidate neoantigens according to predicted immunogenicity.
The computational stage is particularly valuable because a tumour may contain numerous mutations, while only a subset may be useful vaccine targets.

10. Personalized Cancer Vaccines

Cancer is genetically heterogeneous.
Two patients with the same cancer type may have substantially different mutation profiles.

American Journal of Advanced Multidisciplinary Research and Innovation (AJAMRI)

E-ISSN: XXXX-XXXX ● Website: www.ajamri.com ● Email: editor@ajamri.com

This makes cancer an attractive application for personalised vaccines.
An individualised mRNA vaccine can theoretically encode multiple patient-specific tumour antigens.
The objective is to train the immune system to recognise and attack cancer cells carrying those molecular characteristics.
Early clinical research has demonstrated the feasibility of personalised mRNA-based cancer vaccine approaches, although substantial work remains before such strategies become routine across cancer types.

11. Protein Replacement Therapy

Some genetic diseases result from insufficient production of a particular protein.
mRNA could potentially provide temporary instructions for producing the missing or deficient protein.
Potential advantages include:

- No permanent genomic alteration.
- Rapid design.
- Potentially adaptable dosing.
- Ability to target different proteins using the same general platform.

However, achieving sufficient protein production in the appropriate tissues remains a major challenge.

12. Rare Genetic Diseases

Rare diseases frequently involve specific genetic mutations.
Genomic sequencing can identify the molecular defect, while computational methods can assist in designing therapeutic strategies.
A conceptual personalised pathway is:
Patient Genome → Disease Mutation → Missing/Abnormal Protein → Therapeutic Target → mRNA Design
This approach could be particularly valuable for rare disorders where conventional drug development may not be economically attractive.

13. mRNA Delivery Systems

One of the greatest challenges in mRNA therapeutics is delivery.
RNA is relatively fragile and can be degraded rapidly in biological environments.
Delivery systems therefore aim to:
Lipid nanoparticles (LNPs) have become an important delivery technology for mRNA applications.

American Journal of Advanced Multidisciplinary Research and Innovation (AJAMRI)

E-ISSN: XXXX-XXXX ● Website: www.ajamri.com ● Email: editor@ajamri.com

1. Protect the RNA.



2 Transport it through biological barriers.



3 Facilitate cellular uptake



14. Lipid Nanoparticle Technology

Lipid nanoparticles can encapsulate mRNA and help protect it during delivery.

Their properties influence:

- Tissue distribution.
- Cellular uptake.
- RNA release.
- Immune response.
- Therapeutic effectiveness.

Future personalised therapeutics may require delivery systems tailored to specific tissues or clinical applications.

15. Computational mRNA Sequence Design

The coding sequence of an mRNA molecule can be computationally optimised.

Researchers may consider:

- Codon usage.
- RNA structure.
- Translation efficiency.
- Stability.
- Unwanted sequence motifs.
- Immune activation.

AI could potentially optimise these variables simultaneously.

This creates a multi-objective design problem in which improving one property may influence another.

16. Personalized Manufacturing

Conventional pharmaceutical manufacturing generally produces large batches of identical products.

Personalised mRNA therapies may require a different manufacturing model.

A potential workflow is:

Patient Sample → Sequencing → Computational Design → Template Production → mRNA Manufacturing → Quality Control → Patient Administration

Such workflows could potentially reduce the time between molecular diagnosis and treatment.

However, personalised manufacturing creates major challenges in:

- Batch size.
- Cost.
- Quality control.
- Logistics.
- Regulatory approval.

American Journal of Advanced Multidisciplinary Research and Innovation (AJAMRI)

E-ISSN: XXXX-XXXX ● Website: www.ajamri.com ● Email: editor@ajamri.com

- Manufacturing turnaround time.

17. Data Analysis

The conceptual assessment suggests that personalised mRNA therapy is most promising when multiple data streams are integrated.

These can include:

- Whole-genome sequencing.
- Tumour sequencing.
- Transcriptomics.
- Proteomics.
- Clinical records.
- Imaging.
- Immune profiling.

AI can integrate these datasets to identify relationships that may be difficult to detect using conventional statistical approaches.

Table 2. Role of AI Across the Personalized mRNA Pipeline

Stage	AI Application	Potential Benefit
Genomic Analysis	Variant classification	Faster target identification
Target Selection	Predictive modelling	Improved candidate prioritisation
Neoantigen Discovery	Immunogenicity prediction	More targeted vaccine design
Sequence Design	Optimisation algorithms	Improved RNA characteristics
Delivery	Predictive modelling	Better formulation selection
Patient Stratification	Machine learning	More precise treatment selection
Monitoring	Clinical-data analysis	Earlier response detection

18. Applications Beyond Cancer

18.1 Infectious Diseases

Personalised mRNA technologies could potentially be adapted rapidly when pathogen sequences change.

18.2 Autoimmune Diseases

mRNA technologies are being investigated for approaches that could modulate immune responses.

18.3 Regenerative Medicine
mRNA can potentially deliver temporary instructions for proteins involved in tissue repair.

18.4 Cardiovascular Medicine
Research is exploring mRNA-based approaches for vascular and cardiac applications.

18.5 Protein Deficiency Disorders
Temporary protein production may provide therapeutic opportunities for selected metabolic and genetic conditions.

19. Advantages of Personalized mRNA Therapeutics
Potential advantages include:

Rapid Design
Once a molecular target is identified, mRNA sequences can potentially be designed relatively quickly.

Flexible Platform
The same general manufacturing principles can be adapted to different therapeutic sequences.

Temporary Expression
mRNA generally provides transient protein production rather than permanent genomic modification.

Personalisation
Therapeutic sequences can potentially be tailored to individual molecular profiles.

Multi-Target Potential
A single mRNA formulation may potentially encode multiple relevant proteins or antigens.

20. Major Challenges
20.1 RNA Stability
mRNA is susceptible to degradation, requiring appropriate formulation and storage.

20.2 Delivery
Efficiently delivering mRNA to the correct tissue remains a central research challenge.

20.3 Immune Activation
The immune system can recognise RNA and associated delivery components.

The balance between therapeutic activity and unwanted immune responses must therefore be carefully managed.

20.4 Manufacturing

Personalised therapies require highly controlled manufacturing processes with rapid turnaround.

20.5 Cost

Individualised manufacturing can potentially be more expensive than conventional large-batch production.

21. Genomic Privacy

Personalised healthcare relies heavily on genomic information.

Genomic data can contain sensitive information about:

- Disease susceptibility.
- Family relationships.
- Inherited conditions.
- Future health risks.

AI-driven precision medicine therefore requires strong data-governance frameworks.

Important principles include:

- Data minimisation.
- Secure storage.
- Controlled access.
- Patient consent.
- Responsible data sharing.
- Transparent governance.

22. Ethical Considerations

Personalised mRNA medicine raises several ethical questions.

Equity

Will advanced personalised therapies be accessible only to wealthy patients or healthcare systems?

Data Ownership

Who controls genomic information used to develop personalised therapies?

Algorithmic Bias

Could AI systems perform differently across populations because of uneven genomic datasets?

Transparency

Patients need understandable information about how AI contributes to treatment decisions.

23. Regulatory Challenges

Regulatory frameworks must address the distinctive characteristics of personalised therapies.

Important issues include:

- Individualised manufacturing.
- Product consistency.
- Quality control.
- Clinical evidence.
- AI-assisted decision-making.
- Genomic-data protection.
- Long-term monitoring.

Regulators may need new frameworks capable of balancing rapid development with patient safety.

24. Economic and Healthcare-System Implications

Personalised mRNA therapeutics could alter the economics of pharmaceutical development.

Instead of investing primarily in large patient populations, some therapies could be developed for much smaller molecularly defined groups.

This may create opportunities for rare-disease treatment but could also challenge conventional reimbursement models.

Healthcare systems may need new approaches to evaluate:

- Individualised manufacturing costs.
- Clinical effectiveness.
- Long-term benefits.
- Health-economic value.

25. Case Study: Conceptual Personalized Cancer Vaccine Workflow

Consider a patient diagnosed with a genetically heterogeneous tumour.

Step 1: Tumour Sampling

A tumour biopsy is collected.

Step 2: Genomic Sequencing

The tumour and normal tissue are sequenced.

Step 3: Mutation Identification
AI-assisted analysis identifies tumour-specific mutations.

Step 4: Neoantigen Prediction
Candidate neoantigens are computationally ranked.

Step 5: mRNA Design
An mRNA construct encoding selected antigens is designed.

Step 6: Manufacturing
The personalised mRNA formulation is produced and subjected to quality-control testing.

Step 7: Treatment
The patient receives the personalised therapy under an appropriate clinical protocol.

Step 8: Monitoring
Clinical, immune, and molecular data are analysed to assess response.
This example demonstrates how genomics, AI, molecular biology, and personalised medicine can converge into a single therapeutic pipeline.

26. Future Directions

26.1 Real-Time Precision Medicine

Future systems could potentially update treatment strategies continuously as new molecular data become available.

26.2 AI-Driven Therapeutic Design

AI systems may increasingly integrate genomic, structural, immunological, and clinical information.

26.3 Personalised Delivery Systems

Future LNP formulations could potentially be optimised for specific tissues.

26.4 Automated Manufacturing

Robotic manufacturing platforms could shorten the time between sequence design and therapeutic production.

American Journal of Advanced Multidisciplinary Research and Innovation (AJAMRI)

E-ISSN: XXXX-XXXX ● Website: www.ajamri.com ● Email: editor@ajamri.com

26.5 Digital Clinical Twins

Integrated computational models could potentially simulate disease progression and treatment response, supporting more informed therapeutic decisions.

27. Integrated Precision-mRNA Framework

A future precision-mRNA healthcare system can be represented as:

Patient
↓
Genomic + Clinical Data
↓
AI-Based Molecular Analysis
↓
Target Identification
↓
Personalised mRNA Design
↓
Delivery-System Selection
↓
Manufacturing & Quality Control
↓
Therapeutic Administration
↓
Clinical + Molecular Monitoring
↓
AI-Assisted Treatment Optimisation

The final stage creates a feedback loop in which patient outcomes can inform subsequent therapeutic decisions.

28. Questionnaire

Scale: 1 = Strongly Disagree, 5 = Strongly Agree

No.	Statement
1	mRNA technology has significant potential for personalised healthcare.
2	Genomic sequencing can improve the selection of personalised therapeutic targets.
3	AI can accelerate the development of personalised mRNA therapies.
4	Personalised mRNA vaccines could improve cancer treatment strategies.
5	Lipid nanoparticles are important for successful mRNA delivery.

American Journal of Advanced Multidisciplinary Research and Innovation (AJAMRI)

E-ISSN: XXXX-XXXX ● Website: www.ajamri.com ● Email: editor@ajamri.com

No.	Statement
6	Genomic privacy should be a central component of precision medicine.
7	Personalised mRNA therapies require specialised manufacturing systems.
8	AI-based therapeutic decisions require clinical validation.
9	Personalised mRNA therapies could expand treatment options for rare diseases.
10	Equitable access should be considered during the development of personalised mRNA technologies.

29. Policy Recommendations

Governments, healthcare organisations, and biotechnology companies should:

1. Develop secure genomic-data infrastructures.
2. Establish standards for AI-assisted therapeutic design.
3. Support research into tissue-specific mRNA delivery.
4. Invest in scalable personalised manufacturing.
5. Develop regulatory pathways for individualised therapeutics.
6. Promote diverse genomic datasets to reduce algorithmic bias.
7. Strengthen patient-consent frameworks.
8. Encourage interdisciplinary collaboration between genomics, AI, medicine, and biotechnology.
9. Develop reimbursement frameworks for personalised therapies.
10. Ensure that precision-medicine innovations remain accessible across different socioeconomic groups.

30. Discussion

The convergence of mRNA biotechnology, genomics, and artificial intelligence represents a potentially transformative development in precision healthcare.

The central advantage of this convergence is that each technology addresses a different part of the therapeutic problem.

Genomics identifies molecular differences.

AI interprets complex biological data and prioritises potential targets.

mRNA technology provides a flexible mechanism for delivering biological instructions.

Nanoparticle systems facilitate therapeutic delivery.

Clinical monitoring provides feedback on treatment performance.

Together, these components create an integrated precision-medicine ecosystem.

However, technological capability alone will not guarantee clinical success. Personalised therapies must demonstrate safety, efficacy, reproducibility, and economic value.

The development process must therefore combine computational innovation with rigorous laboratory and clinical validation.

31. Conclusion

Personalized mRNA therapeutics represent an important emerging direction in precision healthcare. By combining mRNA technology with genomic profiling and artificial intelligence, researchers may increasingly be able to design therapies around the molecular characteristics of individual patients.

Cancer immunotherapy is currently one of the most prominent areas of development, particularly through personalised neoantigen-based approaches. However, opportunities extend to rare genetic disorders, protein deficiencies, infectious diseases, regenerative medicine, and other therapeutic areas.

AI can contribute by identifying molecular targets, predicting neoantigens, optimising mRNA sequences, stratifying patients, and analysing treatment responses. Genomics provides the information required to understand individual disease biology, while mRNA offers a flexible platform for temporary protein expression.

Significant challenges remain, particularly in delivery, RNA stability, manufacturing, immunogenicity, genomic privacy, regulatory oversight, cost, and equitable access.

The future of personalised mRNA medicine will therefore depend on the successful integration of genomics, AI, molecular engineering, delivery technologies, automated manufacturing, and clinical science.

If these challenges can be addressed responsibly, personalised mRNA therapeutics could help shift healthcare from broadly targeted treatment towards increasingly molecularly informed, adaptive, and patient-specific therapeutic strategies.

References

1. Karikó, Katalin, Buckstein, M., Ni, H., & Weissman, Drew. (2005). Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 23(2), 165–175.
2. Karikó, Katalin, Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, Shizuo, & Weissman, Drew. (2008). Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Molecular Therapy, 16(11), 1833–1840.
3. Pardi, Norbert, Hogan, M. J., Porter, F. W., & Weissman, Drew. (2018). mRNA vaccines—A new era in vaccinology. Nature Reviews Drug Discovery, 17, 261–279.
4. Sahin, Uğur, Kariko, Katalin, & Türeci, Özlem. (2014). mRNA-based therapeutics—Developing a new class of drugs. Nature Reviews Drug Discovery, 13, 759–780.
5. Sahin, Uğur, et al. (2017). Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 547, 222–226.

6. Ott, Patrick A., et al. (2017). An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 547, 217–221.
7. Wang, Yuhong, et al. (2020). The potential of mRNA-based therapeutics in precision medicine. Advanced Drug Delivery Reviews.
8. Hou, Xue, Zaks, T., Langer, Robert, & Dong, Y. (2021). Lipid nanoparticles for mRNA delivery. Nature Reviews Materials, 6, 1078–1094.
9. Cullis, Pieter R., & Hope, M. J. (2017). Lipid nanoparticle systems for enabling gene therapies. Molecular Therapy, 25(7), 1467–1475.
10. Jackson, Nicholas A. C., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020). An mRNA vaccine against SARS-CoV-2—Preliminary report. New England Journal of Medicine, 383, 1920–1931.
11. Polack, Fernando P., et al. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 383, 2603–2615.
12. Bettencourt-Dias, M., et al. (2022). Artificial intelligence and genomics in precision medicine. Nature Reviews Genetics.
13. Topol, Eric. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25, 44–56.
14. Mullard, Asher. (2022). The changing landscape of mRNA therapeutics. Nature Reviews Drug Discovery.
15. National Human Genome Research Institute. (2024). Genomics and Precision Medicine Research. Bethesda, MD.